FDA Brief

Warning letters Drugs

FDA warning letter to

Ehsan Sadri, M.D.

High riskIssued Mar 27Posted Apr 7Center for Drug Evaluation and Research (CDER)

FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.

What happened

FDA inspected Dr. Sadri's clinical site from March 27 to April 16, 2025. FDA found that he enrolled and gave study drug to two subjects who did not meet protocol eligibility criteria: one lacked a required screening cell-density measurement, and one had eye pressure outside the required range. Two of nine randomized and treated subjects at the site were ineligible.

What FDA found

  1. The investigator enrolled a subject who did not have the required central corneal endothelial cell density measurement at screening.

    21 CFR 312.60
  2. The investigator enrolled a subject whose eye pressure at randomization was 16 mmHg in each eye, outside the protocol-required eligibility range.

    21 CFR 312.60
  3. Two of nine randomized and treated subjects at the site were ineligible for enrollment.

    21 CFR 312.60

What FDA wants

FDA tells Dr. Sadri to write within 15 business days describing actions taken to prevent similar violations and to provide enough detail on oversight and procedure changes. It says failure to address the matter adequately may lead to regulatory action without further notice.

Who should pay attention

  • clinical research sites and principal investigators
  • sponsors and CROs relying on site eligibility data
  • IRBs and study monitors overseeing enrollment

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Maria E. De La Torre Silva, M.D.

    Clinical investigator Dr. Maria E. De La Torre Silva enrolled a subject in two drug trials and kept inadequate study-drug records.

    Medium
  3. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  4. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium